<SEC-DOCUMENT>0001628280-23-028563.txt : 20230809
<SEC-HEADER>0001628280-23-028563.hdr.sgml : 20230809
<ACCEPTANCE-DATETIME>20230809160641
ACCESSION NUMBER:		0001628280-23-028563
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230809
DATE AS OF CHANGE:		20230809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		231155134

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20230808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:7f67c1ac-dffb-46f3-9023-79bd149b9093,g:484937cd-8c55-46dd-a7d3-99a5d03b71cb,d:99b81432a5c141cf921a44e8e532cd0f--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230808</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-22">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230808.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i99b81432a5c141cf921a44e8e532cd0f_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 8, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20230808_g1.jpg" alt="crdflogo.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-18">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-19">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2023.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 5.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, Cardiff Oncology, Inc. (the &#8220;Company&#8221;) filed, with the Secretary of State of the State of Delaware, a Certificate of Elimination (the &#8220;Certificate of Elimination&#8221;) of Series B, Series C, Series D and Series E Convertible Preferred Stock removing the designation and other references to its Series B, Series C, Series D and Series E Convertible Stock from the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended.  The Certificate of Elimination eliminates and returns the 8,860, 200,000, 154,670 and 865,825 shares of preferred stock previously designated as Series B, Series C, Series D and Series E Preferred Stock, respectively, and no longer issued and outstanding, to the status of authorized but unissued shares of preferred stock, without designation. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Certificate of Elimination does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Elimination, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a31ex080823.htm">Certificate of Elimination of Series B, Series C, Series D and Series E Convertible Preferred Stock dated as of August </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a31ex080823.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a31ex080823.htm">, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf063023-q22023pr.htm">Press Release of Cardiff Oncology, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf063023-q22023pr.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf063023-q22023pr.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf063023-q22023pr.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf063023-q22023pr.htm">, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> August 9, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>a31ex080823.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f41c6b5ee854432a37fa5b529eec89a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CARDIFF ONCOLOGY, INC. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATE OF ELIMINATION </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERIES B, SERIES C, SERIES D AND SERIES E CONVERTIBLE PREFERRED STOCK</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section 151(g) of the General Corporation Law of the State of </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cardiff Oncology, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DOES HEREBY CERTIFY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to the authority expressly vested in the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by the Amended and Restated Certificate of Incorporation of the Company, as amended, the Board previously adopted resolutions creating and authorizing the issuance of (i) 8,860 shares of Series B Convertible Preferred Stock (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Series B Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) in accordance with the provisions of the Certificate of Designation of Series B Preferred Stock as filed with the Delaware Secretary of State on June 8, 2018, (ii) 200,000 shares of Series C Convertible Preferred Stock (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Series C Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) in accordance with the provisions of the Certificate of Designation of Series C Preferred Stock as filed with the Delaware Secretary of State on January 25, 2019, as amended by that certain Amendment to Certificate of Designation of Series C Preferred Stock filed on January 28, 2019,  (iii) 154,670 shares of Series D Convertible Preferred Stock (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Series D Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) in accordance with the provisions of the Certificate of Designation of Series D Preferred Stock as filed with the Delaware Secretary of State on May 8, 2020 and (iv) 865,824 shares of Series E Convertible Preferred Stock (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Series E Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) in accordance with the provisions of the Certificate of Designation of Series E Preferred Stock as filed with the Delaware Secretary of State on June 16, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECOND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to Section 151(g) of the DGCL, the Board adopted the following resolutions respecting the Company&#8217;s Series B, Series C, Series D and Series E Preferred Stock, which resolutions have not been amended or rescinded&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, BE IT HEREBY RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Chief Executive Officer and Chief Financial Officer (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Authorized Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Authorized Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) be, and each of them individually hereby is, authorized and empowered, in the name and on behalf of the Company, to prepare and file with the Delaware Secretary of State a Certificate of Elimination or other certificate to remove the designation and other references to the Series B, Series C, Series D and Series E Preferred Stock from the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, that are contained in each of the Certificate of Designation of Series B , Series C, Series D and Series E Preferred Stock, and will eliminate and return the 8,860, 200,000, 154,670 and 865,825 shares of preferred stock previously designated as Series B, Series C, Series D and Series E Preferred Stock, respectively, to the status of authorized but unissued shares of preferred stock, without designation, in a form approved by the Authorized Officer executing the same, such approval to be conclusively evidenced by the Authorized Officer's execution thereof, and one or more amendments thereto, as such Authorized Officer may deem necessary, advisable, or appropriate or as may be required by the Delaware Secretary of State&#59; and be it further</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;RESOLVED, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that effective on and after the date of effectiveness of the Certificate of Amendment, none of the authorized shares of Series B, Series C, Series D and Series E Preferred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock are outstanding, and none will be issued subject to the Certificate of Designation of Series B, Series C, Series D and Series E Preferred Stock, previously filed with the Delaware Secretary of State with respect to the Series B, Series C, Series D and Series E Preferred Stock, respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;THIRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In accordance with Section 151(g) of the DGCL, all matters set forth in the previously filed Certificate of Designation of each of Series B, Series C, Series D and Series E Preferred Stock are hereby eliminated.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Cardiff Oncology, Inc. has caused this Certificate of Elimination of Series B, Series C, Series D and Series E Preferred Stock to be duly executed by the undersigned duly authorized officer of the Company as of August 8, 2023</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Erlander</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Mark Erlander</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   CEO</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>crdf063023-q22023pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i16f9370f07ff46a7b871a8bc47721f70_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:270px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:139%">Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship&#59; interim topline data expected in mid-2024 -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">- Advance to first-line mCRC follows strong signal from new clinical and preclinical findings and guidance from FDA, and represents an increased market opportunity -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">- Cash, cash equivalents, and short-term investments of approximately $89.4 million as of June 30, 2023, projected runway into 2025 -</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">SAN DIEGO,&#160;August 9, 2023&#160;-&#160;Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended&#160;June 30, 2023, and provided a business update.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8220;2023 has been transformative for Cardiff Oncology, highlighted by the advancement of our lead program to the first-line mCRC setting and an expansion of our relationship with Pfizer,&#8221; said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. &#8220;The shifting of our clinical development program to the first-line was a data-driven decision based on a strong signal from new clinical and preclinical findings, with agreement from the FDA. There are 48,000 new patients in the U.S. annually in the first-line RAS-mutated mCRC setting, with no ongoing clinical trials or new treatments approved in the past 20 years. We believe that there is a tremendous opportunity for onvansertib to provide a meaningful benefit to a substantial number of patients who are fighting cancer in challenging indications. Looking ahead, we anticipate commencing enrollment in our first-line trial this fall with interim topline data expected in mid-2024.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Upcoming expected milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:14.5pt">mPDAC data readout from Phase 2 trial expected in Q3 '23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:14.5pt">SCLC data readout from Phase 2 trial expected in Q3 '23 (investigator-initiated trial with UPMC)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:14.5pt">First patient dosed in first-line mCRC trial expected fall &#8216;23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:14.5pt">TNBC data readout from Phase&#160;1b&#47;2 trial expected Q4 '23&#47;Q1 '24 (investigator-initiated trial with Dana-Farber Cancer Institute) </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:14.5pt">First-line mCRC randomized data readout expected in mid-2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Company highlights for the quarter ended June 30, 2023 and resent announcements </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:13.8pt">Announced new lead program in mCRC and expanded Pfizer relationship. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:13.8pt">Cardiff Oncology will initiate a first-line trial, CRDF-004, a Phase 2 randomized trial generating preliminary safety and efficacy data and evaluating two different doses of onvansertib to confirm an optimal dose. Onvansertib will be added to standard-of-care consisting of FOLFIRI plus bevacizumab, or FOLFOX plus bevacizumab. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:13.8pt">Contingent upon the results of CRDF-004, Cardiff Oncology will initiate CRDF-005, a Phase 3, randomized trial with registrational intent. The FDA has agreed that a seamless trial with objective response rate at an interim point is an acceptable endpoint to pursue accelerated approval, with progression-free survival and trend in overall survival being the endpoints for full approval.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:13.8pt">Pfizer Ignite will be responsible for the clinical execution of the CRDF-004 trail, leveraging Pfizer&#8217;s significant R&#38;D capabilities, scale and expertise.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:13.8pt">Our new partnership with Pfizer Ignite expands the relationship established in November 2021 when Pfizer made an equity investment in Cardiff Oncology and nominated Adam Schayowitz, Ph.D., Vice President &#38; Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer Global Product Development as a Scientific Advisory Board member.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">Second Quarter 2023 Financial Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">Liquidity, cash burn, and cash runway</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">As of&#160;June 30, 2023, Cardiff Oncology had approximately&#160;$89.4 million in cash, cash equivalents, and short-term investments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Net cash used in operating activities for the second quarter of 2023 was approximately&#160;$7.1 million, an </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">increase </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">of approximately&#160;$0.4 million&#160;from&#160;$6.7 million&#160;for the same period in 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">Operating results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Total operating expenses were approximately&#160;$12.3 million&#160;for the three months ended June 30, 2023, an increase of&#160;$1.8 million&#160;from&#160;$10.5 million&#160;for the same period in 2022. The increase in operating expenses was primarily due to higher salaries and staff costs primarily due to increased headcount and stock-based compensation for additional grants to employees.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">About Cardiff Oncology, Inc.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended&#160;December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Cardiff Oncology Contact&#58;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">James Levine&#160;<br>Chief Financial Officer&#160;<br>858-952-7670&#160;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">jlevine&#64;cardiffoncology.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Investor Contact&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;<br>Kiki Patel, PharmD &#160;<br>Gilmartin Group&#160;&#160;<br>332-895-3225<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Kiki&#64;gilmartinir.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Media Contact&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;<br>Richa Kumari&#160;<br>Taft Communications&#160;&#160;<br>551 344-5592&#8239;&#160;&#160;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">richa&#64;taftcommunications.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i16f9370f07ff46a7b871a8bc47721f70_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands, except for per share amounts)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,020&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,072&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,656&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,026&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,316&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,451&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,682&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,208)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,443)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,260)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,517)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,150)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,443)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,373)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,436)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,156)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,449)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,385)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,448)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,306&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,269&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i16f9370f07ff46a7b871a8bc47721f70_7"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Balance Sheets</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,731&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,284&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,455&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,876&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,848&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,579&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,455&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i16f9370f07ff46a7b871a8bc47721f70_10"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Cash Flows</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,373)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,436)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,791)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,944)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, maturities and sales of short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,072&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,813&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,966&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,369&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,965&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crdf-20230808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7f67c1ac-dffb-46f3-9023-79bd149b9093,g:484937cd-8c55-46dd-a7d3-99a5d03b71cb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230808" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230808">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crdf-20230808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7f67c1ac-dffb-46f3-9023-79bd149b9093,g:484937cd-8c55-46dd-a7d3-99a5d03b71cb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_4ab23d5b-cf7c-4af9-ac85-094f3f3a1b7a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_489da5cc-953b-45f3-86a9-f3901ac694cd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c2fccb38-9eb0-4e24-9a64-aba0f2e88aab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2c377c6a-aeb3-4d3e-bc83-41097f5e06be_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b8916e63-8d5a-4210-be79-8ac13b91944c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0e7eec4d-63db-49b4-a34c-139f309c7e7d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_da951484-dc19-47a5-b325-a6185f40c72f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8370eb27-80e7-4e74-9111-ca9f1cf6652c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_65f6753c-5997-4192-99ca-552930d15dbe_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_15eab38a-a149-4356-855e-2d1fad60b3b7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_98779ab1-e502-42cf-b509-d10e812c2d87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c505f55d-218a-4f2c-87e5-c985627187c0_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe1ef737-6806-4699-8631-c10830c694a3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e8e976d8-27d2-4209-9306-877d36746219_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1c321296-17b5-4402-b085-2f6f6cdcb5dc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3f7f13a5-47ff-4e65-ac6c-7392cb01b76e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1125572f-c576-4920-a0aa-404f9ac6c1cc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_55bfa368-8b85-4be5-8ae4-3519e38fcea6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6e0676bf-fd5f-4871-91ad-1684692dd745_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4ced59c4-5db6-47be-b63c-a7eed11909e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f39df7ce-fea1-4d0f-9ef3-c5174ea91f49_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_6cfb5e96-301e-46d3-946d-64b82f3a072c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crdf-20230808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7f67c1ac-dffb-46f3-9023-79bd149b9093,g:484937cd-8c55-46dd-a7d3-99a5d03b71cb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20230808.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c6a163e4-3fa3-47aa-a37c-ad756525d266" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_DocumentType_c6a163e4-3fa3-47aa-a37c-ad756525d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_21f41279-34dd-4032-bc3c-b99b8bc4a3b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_DocumentPeriodEndDate_21f41279-34dd-4032-bc3c-b99b8bc4a3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_34df8d72-3524-473e-bed2-4f829044e5df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityRegistrantName_34df8d72-3524-473e-bed2-4f829044e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7f99cf3a-1b1c-40b9-85f8-c5428f93c2db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityFileNumber_7f99cf3a-1b1c-40b9-85f8-c5428f93c2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c27c9447-8c1f-4161-897f-b612d5d1b1e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityTaxIdentificationNumber_c27c9447-8c1f-4161-897f-b612d5d1b1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c06cbba-e2ef-44ab-b64a-f320b57f5c58" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityAddressAddressLine1_1c06cbba-e2ef-44ab-b64a-f320b57f5c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_00847a9a-9a45-4a4f-8685-de50c5cef2e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityAddressStateOrProvince_00847a9a-9a45-4a4f-8685-de50c5cef2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cd7d70d0-17e7-4f1f-bf05-3562471da138" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityAddressPostalZipCode_cd7d70d0-17e7-4f1f-bf05-3562471da138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d351245e-3ddd-49c9-9ed4-f421f88068bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityAddressCityOrTown_d351245e-3ddd-49c9-9ed4-f421f88068bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e2678f46-1e7e-4737-bdfd-7c1a314815ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_CityAreaCode_e2678f46-1e7e-4737-bdfd-7c1a314815ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_87502f2f-91b7-4a59-b698-084d17c37ddd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_LocalPhoneNumber_87502f2f-91b7-4a59-b698-084d17c37ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_02ee81e0-4f85-48d0-a53e-87a9d1475465" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_Security12bTitle_02ee81e0-4f85-48d0-a53e-87a9d1475465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e374739f-bc14-466a-a4cc-23f323d86038" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_TradingSymbol_e374739f-bc14-466a-a4cc-23f323d86038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e04e853b-312c-4052-a33c-56078ccceb57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_WrittenCommunications_e04e853b-312c-4052-a33c-56078ccceb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d3a5ff56-387c-4185-b393-340146dba38f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_SolicitingMaterial_d3a5ff56-387c-4185-b393-340146dba38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_98321659-fa77-453e-81d6-e82038ad509c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_PreCommencementTenderOffer_98321659-fa77-453e-81d6-e82038ad509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_485cdd19-424e-4a67-b4c4-19a1c846d584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_485cdd19-424e-4a67-b4c4-19a1c846d584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fff0b54d-38c0-459b-800f-6bed63132e05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityEmergingGrowthCompany_fff0b54d-38c0-459b-800f-6bed63132e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fe4a993d-8a9c-4418-9882-c971aecd0567" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fe4a993d-8a9c-4418-9882-c971aecd0567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2f4e0314-2e5a-4bf2-82ef-a20073b170fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_EntityCentralIndexKey_2f4e0314-2e5a-4bf2-82ef-a20073b170fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_01437f77-eab7-4d85-b244-c682e5167a40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_AmendmentFlag_01437f77-eab7-4d85-b244-c682e5167a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c59c4fc4-6588-41ee-898f-bf1e6709b349" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_04b83823-993c-4cd1-b6fd-a2e9402e86d7" xlink:to="loc_dei_CurrentFiscalYearEndDate_c59c4fc4-6588-41ee-898f-bf1e6709b349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>crdf-20230808_g1.jpg
<TEXT>
begin 644 crdf-20230808_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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5 7)+M=N/[L%'     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139651585425312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>crdf-20230808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20230808.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-22">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ U( )5ZK$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #4@ E799!YDAD!  #/ P  $P
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M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -2
M"5<'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ U( )5T02J'/O    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ U( )5YE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #4@ E7D'X\5S<$  !U$   &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ U( )5Y^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #4@ E7EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #4@ E7JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ U( )5R0>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ U( )5V60>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20230808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20230808.htm">crdf-20230808.htm</File>
    <File>a31ex080823.htm</File>
    <File>crdf-20230808.xsd</File>
    <File>crdf-20230808_lab.xml</File>
    <File>crdf-20230808_pre.xml</File>
    <File>crdf063023-q22023pr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20230808_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230808.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20230808.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230808_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230808",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-23-028563-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-028563-xbrl.zip
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MXS2<M>TS"C:ET7:FL!=IM@:@2@7>J*K3A-8H%!8-\9C=LW!J#^B.:%!M1TF
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MN(\FAYNE,[?>R=HSXB^=5,_OG.T0</RPG/-&E9!?^TST3L\^YP\I['=V;,^
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M8R+OTH&V[:?4@PI<SG\VR/[[0GVH+EJ[3E3Q-%XOJ@N@THUJ#2PV/96X,^/
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M&OY(Y^"G< *^W]GW/J?>M[^)<W-U^FKS3K3ZV>W35_\#4$L#!!0    ( -2
M"5>.<Y2LMP8  /@P   5    8W)D9BTR,#(S,#@P.%]P<F4N>&ULU5K;4N-(
M$GWG*[S>URU<5U45T3#!,MT;Q##31#<3,[LOCKID@6)DB2B+!OY^4P+/- WL
M*I CK'[Q14[I9)T\SLI,Z=T/=ZMJ]@7RNFSJPSG;I_,9U*&)97UY./_UX@,Q
M\Q^.]O;>_8V0W__YZ6SV8Q-N5E"WLY,,KH4XNRW;JUE[!;/?FOQ'^<7-SBO7
MIB:O"#GJ3SMIKN]S>7G5SCCE8F.V^34?Z%3HP%P@,25/9)$$L6A(M/612>LM
MM>(?EP?22"MTB,0$I= L1N)T1%OK5*3":Q9\?]&JK/\XZ%Z\6\,,EU>O^Z^'
M\ZNVO3Y8+&YO;_?O?*[VFWRYX)2*Q<9Z_FA^]\S^5O36S%J[Z'_]TW1=OF2(
MEV6+WW\^^QRN8.5(6:];5X<.8%T>K/N#9TUP;<_Z__5K]JI%]XULS$AWB#!.
M!-N_6\?YT=YL]D!';BKX!&G6O?_ZZ?0)9' YEBDU&/6JN;S?#\UJT=DM3AK4
M!7K<7Z&]OX;#^;I<75>P.7:5(1W.0XZ)=*&EAIH.]^\/)R[^@K_.L$;-],L]
MPP./YW<H;W8%[EJH(SRL<@-4->&)4=5QW/QY9N4\5/W1981RV5_UV*_;[$*[
MI-(;87BG*!&(#)$17R14&0<K*0=31/UTY9WG:W2]#\D:POYE\V6!%\;0<-Y]
MZ&CA/27/X![H>9O?F__@!=HN0^%8(4 2D9P@4CM''/Y/B(M:%8JKR(MBE-M?
MHSWU^NNP'N<P:W*$C$ED ^=R>!;BI_)]M%A<NXP7(N&JK.+F[)2;U39BU39;
M8.XA+.CN?(:K3I SQ+.'J+RZN'YE+:96Z"VW$?%SR&43W]?Q1\R]2\Z29%Q;
M(B1F0TD%)SX@']Y:;WR03GBZE= _@1VD 3Y]#;R=RQV+X7W=ENW])[@L.R;J
M]A>W@B6ZG4S4F/L5ERAF <1#Y$0FPRV5$E1,H[3P$NH@*8CI2F$TDY-0PH>R
M@E]N5A[R4B=K0Q*.,,^0".HM,2H9$I3D)B$Y//HMJ. OQ$$*D%-7P!L9G$3T
M+]S=:42NRE0^U)./"PE<!RNEQGJ9)2)9P8BQ.B$MC$<5<7E@MB"%5^ 'Z4)-
M71?;X'82(CF.$4.P?GS#$AS8D@5:!.\= 0ZX".D\^B\=28)3KW1206U#("]
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M3HY[CNX)W+#H3WAD^7;R=GV'XB9W#'THU\%5_P:7-P__!66#3%@0%<H8[+4
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M.E&8Y>&U8PNSZ6-. 34(93G6TN?/KM3E\PPRD2;2H_;%688KJ^K$V:16VO/
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MW<8.YQ=7;?YOA"?&?1&QAD,X<)=P<(0$T^:I/WZ*Z54<+YJD>\0SQ]M><M>
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M8-4&"WW_Y>@5*'67KD^J= !78JWI&S$!"9/\WMVR):Q5=^_9YU,@OZ"BI*G
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M,65X,#@P.#(S+FAT;5!+ 0(4 Q0    ( -2 "5>+EZ4<51$  !Z+   1
M          "  <\(  !C<F1F+3(P,C,P.# X+FAT;5!+ 0(4 Q0    ( -2
M"5>?O?9"<0(  (4'   1              "  5,:  !C<F1F+3(P,C,P.# X
M+GAS9%!+ 0(4 Q0    ( -2 "5>GUJOO PH  *P*   4              "
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9:'1M4$L%!@     '  < R $  "U7      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
